Barrick Mining Corporation Stock Price, News & Analysis

BioArctic AB's partner Eisai reported Leqembi® global revenue of JPY 10 billion for Q3 2024, marking a 60% increase from Q2 2024's JPY 6.3 billion. This resulted in a royalty payment of approximately SEK 70 million to BioArctic. Eisai leads Leqembi's development and regulatory submissions globally, with Biogen co-commercializing the product. BioArctic maintains commercialization rights in the Nordic region and is preparing for joint commercialization with Eisai pending European approval.

BioArctic AB announced that its co-founder, Professor Lars Lannfelt, received the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the CTAD congress in Madrid. The award recognizes his pioneering work in Alzheimer's disease research and drug development, particularly his contributions leading to lecanemab, a disease-modifying treatment for early Alzheimer's approved in multiple countries including the U.S., Japan, and China. Lannfelt founded BioArctic in 2003 with Pär Gellerfors to develop antibody treatments based on his discoveries about amyloid-beta protein's role in Alzheimer's disease. Lecanemab, developed in collaboration with Eisai, works by binding to and clearing specific forms of amyloid-beta from the brain.

Barnes Group Inc. (NYSE: B) reported third quarter 2024 financial results with sales of $388 million, up 7% year-over-year with organic growth of 4%. The company posted a net loss of $2.1 million, or -$0.04 per share, while adjusted EPS was $0.09. Notable highlights include strong Aerospace performance with a 49% increase in segment sales to $232 million and a significant OEM backlog of $1.80 billion. The company recently announced its pending acquisition by Apollo Funds for $47.50 per share in cash, valuing Barnes at approximately $3.6 billion enterprise value.

Hexagon AB announces plans to evaluate separating its Asset Lifecycle Intelligence (ALI) business through a Lex Asea distribution to shareholders. The new company ('NewCo') would include ETQ, Bricsys, and Utilities & Infrastructure businesses. NewCo, with approximately 5,000 employees, generated revenues of EUR 980 million with a 35% adjusted operating margin. The remaining Hexagon business has 19,600 employees with revenues of EUR 4,408 million and 28% adjusted operating margin. Mattias Stenberg, current ALI division President, would lead NewCo. The separation process is expected to take 12-18 months and requires board and shareholder approval.

BioArctic AB announced that its founder, Lars Lannfelt, will receive the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the CTAD Conference in Madrid from October 29 to November 1. The conference will feature presentations on lecanemab, including data on its clinical practice use and plasma biomarkers in the AHEAD 3-45 trial. Key sessions include three symposia focusing on lecanemab's continued treatment importance, real-world evidence from the U.S. and Japan, and combination therapy considerations. Two oral presentations will discuss lecanemab's treatment efficacy and AI-derived prognostic covariates, along with a poster presentation on transitioning from clinical trials to practice.

BioArctic AB's partner Eisai announced that Australia's Therapeutic Goods Administration (TGA) initially decided not to register lecanemab, an antibody for treating mild cognitive impairment and mild dementia due to Alzheimer's disease. Eisai plans to request reconsideration within 90 days, with TGA's final decision expected 60 days after. Lecanemab, developed through BioArctic and Eisai's collaboration, is already approved in several countries including the US, Japan, and China.

The antibody originated from BioArctic's research based on Professor Lars Lannfelt's work. Eisai leads global development and regulatory submissions, with Eisai and Biogen co-commercializing the product. BioArctic retains commercialization rights in the Nordic region and is preparing for joint commercialization with Eisai in Europe, pending approval.

Nearmap, a global leader in location intelligence solutions, has announced the expansion of its imagery coverage across the U.S. through a partnership with Hexagon's Content Program. This addition complements Nearmap's existing coverage of 87% of the U.S. population, allowing insurers to gain insights into less populated geographic regions.

The expanded coverage will be accessible through Partner Connect, the Betterview platform's ecosystem for integrating third-party geospatial datasets and tools. This enhancement enables insurance companies to:

• Optimize underwriting efficiency
• Reduce physical inspection spending
• Recommend risk mitigation steps to policyholders

Nearmap surveys over 100 million parcels in the United States up to three times per year, providing insurance companies with valuable location insights for better-informed decisions across the entire policy lifecycle.

ETQ, part of Hexagon, has launched the ETQ Reliance® Predictive Quality Analytics solution, integrating AI-driven analytics into its quality management system (QMS). This solution, developed in partnership with Acerta Analytics, enables automated early detection and proactive resolution of manufacturing issues.

Key features include:

• Manufacturing-specific data ingestion
• Advanced data analysis
• Predictive monitoring and alerts
• Automated root cause analysis

The solution aims to prevent production problems, limit variation, speed decision-making, and improve overall quality. It combines Acerta's LinePulse AI and machine learning technology with ETQ Reliance's advanced quality workflows, creating a predictive, closed-loop quality system.

This launch addresses manufacturers' concerns about plant performance, operational efficiency, compliance, risk management, and product recalls. The solution is available immediately for both new and existing ETQ Reliance NXG customers.

Barnes Group Inc. (NYSE: B) has announced an agreement to be acquired by funds managed by affiliates of Apollo Global Management, Inc. (NYSE: APO) in an all-cash transaction valued at approximately $3.6 billion. Barnes shareholders will receive $47.50 per share in cash, representing a premium of about 22% over Barnes' undisturbed closing share price on June 25, 2024.

The transaction, expected to close before the end of Q1 2025, is subject to approval by Barnes shareholders and regulatory approvals. Upon completion, Barnes will become a privately held company but continue to operate under the Barnes Group name and brand. The Barnes Board of Directors unanimously approved the agreement and recommends shareholders vote in favor.

As a result of this pending transaction, Barnes has suspended its financial guidance for the full year 2024 and will not conduct its third quarter 2024 conference call and webcast.